{"id":28701,"date":"2025-03-04T21:53:47","date_gmt":"2025-03-04T13:53:47","guid":{"rendered":"https:\/\/flcube.com\/?p=28701"},"modified":"2025-03-07T22:50:53","modified_gmt":"2025-03-07T14:50:53","slug":"boehringer-ingelheim-appeals-cnipas-invalidation-of-jardiance-patents","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=28701","title":{"rendered":"Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents"},"content":{"rendered":"\n

The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding a hearing on the case of administrative dispute over the invalidity of invention patent between the appellant Boehringer Ingelheim and the appellee China National Intellectual Property Administration (CNIPA), as well as third parties of first instance Hansoh Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., CTTQ Pharma, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., and Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.<\/p>\n\n\n\n

Patent Dispute Background<\/strong>
BI sued CNIPA and the Chinese companies due to a patent dispute concerning Jardiance (empagliflozin), an SGLT2 inhibitor co-developed by Eli Lilly and approved in the US and China in 2014 and 2017 respectively. A slew of domestic companies, including those mentioned above, have challenged the drug’s patent since, with CNIPA declaring all patents of empagliflozin invalid in September 2020.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding…<\/p>\n","protected":false},"author":1,"featured_media":28702,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[390,661,2658,199,3834,114,371,73],"class_list":["post-28701","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-boehringer-ingelheim","tag-chia-tai-tianqing-pharmaceutical","tag-cttq-pharma","tag-eli-lilly","tag-fosun-wanbang-pharmaceutical","tag-huadong-medicine","tag-kelun-pharmaceutical","tag-patents"],"yoast_head":"\nBoehringer Ingelheim Appeals CNIPA's Invalidation of Jardiance Patents - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Intellectual Property Court of the Supreme People's Court of China issued a notice, holding a hearing on the case of administrative dispute over the invalidity of invention patent between the appellant Boehringer Ingelheim and the appellee China National Intellectual Property Administration (CNIPA), as well as third parties of first instance Hansoh Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., CTTQ Pharma, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., and Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=28701\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim Appeals CNIPA's Invalidation of Jardiance Patents\" \/>\n<meta property=\"og:description\" content=\"The Intellectual Property Court of the Supreme People's Court of China issued a notice, holding a hearing on the case of administrative dispute over the invalidity of invention patent between the appellant Boehringer Ingelheim and the appellee China National Intellectual Property Administration (CNIPA), as well as third parties of first instance Hansoh Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., CTTQ Pharma, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., and Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=28701\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-04T13:53:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-07T14:50:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0402-1-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28701#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28701\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents\",\"datePublished\":\"2025-03-04T13:53:47+00:00\",\"dateModified\":\"2025-03-07T14:50:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28701\"},\"wordCount\":151,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28701#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0402-1-png.avif\",\"keywords\":[\"Boehringer Ingelheim\",\"Chia Tai Tianqing Pharmaceutical\",\"CTTQ Pharma\",\"Eli Lilly\",\"Fosun Wanbang Pharmaceutical\",\"Huadong Medicine\",\"Kelun Pharmaceutical\",\"Patents\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28701#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28701\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=28701\",\"name\":\"Boehringer Ingelheim Appeals CNIPA's Invalidation of Jardiance Patents - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28701#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28701#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0402-1-png.avif\",\"datePublished\":\"2025-03-04T13:53:47+00:00\",\"dateModified\":\"2025-03-07T14:50:53+00:00\",\"description\":\"The Intellectual Property Court of the Supreme People's Court of China issued a notice, holding a hearing on the case of administrative dispute over the invalidity of invention patent between the appellant Boehringer Ingelheim and the appellee China National Intellectual Property Administration (CNIPA), as well as third parties of first instance Hansoh Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., CTTQ Pharma, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., and Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28701#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28701\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28701#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0402-1-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0402-1-png.avif\",\"width\":1080,\"height\":608,\"caption\":\"Boehringer Ingelheim Appeals CNIPA's Invalidation of Jardiance Patents\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28701#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim Appeals CNIPA's Invalidation of Jardiance Patents - Insight, China's Pharmaceutical Industry","description":"The Intellectual Property Court of the Supreme People's Court of China issued a notice, holding a hearing on the case of administrative dispute over the invalidity of invention patent between the appellant Boehringer Ingelheim and the appellee China National Intellectual Property Administration (CNIPA), as well as third parties of first instance Hansoh Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., CTTQ Pharma, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., and Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=28701","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim Appeals CNIPA's Invalidation of Jardiance Patents","og_description":"The Intellectual Property Court of the Supreme People's Court of China issued a notice, holding a hearing on the case of administrative dispute over the invalidity of invention patent between the appellant Boehringer Ingelheim and the appellee China National Intellectual Property Administration (CNIPA), as well as third parties of first instance Hansoh Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., CTTQ Pharma, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., and Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.","og_url":"https:\/\/flcube.com\/?p=28701","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-04T13:53:47+00:00","article_modified_time":"2025-03-07T14:50:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0402-1-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=28701#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=28701"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents","datePublished":"2025-03-04T13:53:47+00:00","dateModified":"2025-03-07T14:50:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=28701"},"wordCount":151,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=28701#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0402-1-png.avif","keywords":["Boehringer Ingelheim","Chia Tai Tianqing Pharmaceutical","CTTQ Pharma","Eli Lilly","Fosun Wanbang Pharmaceutical","Huadong Medicine","Kelun Pharmaceutical","Patents"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=28701#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=28701","url":"https:\/\/flcube.com\/?p=28701","name":"Boehringer Ingelheim Appeals CNIPA's Invalidation of Jardiance Patents - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=28701#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=28701#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0402-1-png.avif","datePublished":"2025-03-04T13:53:47+00:00","dateModified":"2025-03-07T14:50:53+00:00","description":"The Intellectual Property Court of the Supreme People's Court of China issued a notice, holding a hearing on the case of administrative dispute over the invalidity of invention patent between the appellant Boehringer Ingelheim and the appellee China National Intellectual Property Administration (CNIPA), as well as third parties of first instance Hansoh Pharmaceutical, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., CTTQ Pharma, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., and Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=28701#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=28701"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=28701#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0402-1-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0402-1-png.avif","width":1080,"height":608,"caption":"Boehringer Ingelheim Appeals CNIPA's Invalidation of Jardiance Patents"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=28701#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0402-1-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28701"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28701\/revisions"}],"predecessor-version":[{"id":28703,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28701\/revisions\/28703"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/28702"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}